Results for tag: "Unituxin"

Unituxin (dinutuximab) is an oncology drug used to treat high-risk neuroblastoma, a type of cancer that affects the nervous system. It is a monoclonal antibody that binds to a protein called GD2, which is found on the surface of neuroblastoma cells. Unituxin is used in combination with other drugs, such as chemotherapy and radiation therapy, to treat high-risk neuroblastoma. It is also used to prevent the recurrence of neuroblastoma in patients who have already been treated. Unituxin is approved by the US Food and Drug Administration (FDA) for the treatment of high-risk neuroblastoma in children aged 12 months to 17 years. It is also approved in Europe and other countries. Unituxin is marketed by Merck & Co., Inc. in the United States and by EUSA Pharma in Europe. Other companies involved in the market include Pfizer, Novartis, and AstraZeneca. Show Less Read more